Lessons From ASCO 2026

Precision oncology's next leap depends on biomarkers, data, and AI, with pathology at the center, say experts

Category	Detail
Condition	Precision Oncology
Key Mechanisms	Integration of pathology with biomarker-driven therapies and AI-supported insights.
Target Population	Patients requiring targeted therapies based on tumor profiling.
Care Setting	Oncology clinics and pathology laboratories.

Pathology is becoming central to precision oncology, acting as a control point for therapeutic innovation.
The shift towards biomarker-driven clinical trials necessitates more actionable insights from limited tissue samples.
AI and digital pathology are transforming how clinicians derive insights from diagnostic images.
Combination therapies are on the rise, increasing the complexity of treatment selection.
Integrated workflows are essential for synthesizing multimodal data into actionable patient profiles.

Implement AI-supported analysis to enhance diagnostic confidence and treatment selection.

Ensure timely turnaround of biomarker results to facilitate prompt treatment initiation.

Address the challenges of limited tissue availability in the context of expanding therapeutic options.

Patients with cancer requiring personalized treatment approaches.

Emphasis on biomarker-driven patient selection for targeted therapies.

Adopt validated workflows across laboratories to ensure consistency in pathology assessments.
Foster collaboration between pathologists, clinicians, and researchers to enhance patient care.